The EBV+ GC subtype is also characterized by amplification of JAK2, ERBB2, and programmed cell death ligand 1⁄2 (PD-L1/2), the latter with an important role as targets of immunotherapy in the treatment of GC. The gene discussed is JAK2; the disease is gastric cancer.